Literature DB >> 16343679

Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders.

Annalisa Berzigotti1, Maria Francesca Rinaldi, Donatella Magalotti, Maria Cristina Morelli, Paola Zappoli, Pietro Andreone, Cristina Rossi, Marco Zoli.   

Abstract

BACKGROUND/AIMS: We aimed to characterize by echo-color-Doppler the splanchnic hemodynamics of patients good and poor responders to primary prophylaxis with nadolol.
METHODS: Thirty cirrhotic patients (Child-score 7.0+/-1.8) with medium/large esophageal varices without previous bleedings were consecutively enrolled. At inclusion and after 3 months of treatment with nadolol, they underwent a splanchnic echo-color-Doppler study and a measurement of hepatic venous pressure gradient (HVPG).
RESULTS: Nadolol (60+/-36 mg/day; range 20-160) induced a significant reduction of HVPG (16.6+/-6.1 vs. 19.4+/-4.6 mmHg, P < 0.0001). 13 patients (43.3%) were hemodynamic responders. Responders and Poor-responders had similar baseline clinical characteristics. Poor-responders at baseline were characterized by lower impedance indexes in superior mesenteric artery (SMA) (PI 2.29+/-0.45 vs. 2.74+/-0.46; P = 0.01; RI 0.83+/-0.04 vs. 0.86+/-0.03; P = 0.02), hepatic artery (HA) (PI 1.41+/-0.19 vs. 1.79+/-0.48; P = 0.03; RI 0.71+/-0.05 vs. 0.80+/-0.07; P = 0.02), and splenic artery (SA) (PI 1.18+/-0.27 vs. 1.73+/-0.40; P = 0.01; RI 0.66+/-0.07 vs. 0.73+/-0.09; P = 0.02), and by higher mean flow velocity of HA (52.6+/-21.6 vs. 26.5+/-9.5 cm/s; P = 0.02) and SMA (49.7+/-14.5 vs. 33.9+/-13.1 cm/s; P = 0.06).
CONCLUSIONS: Cirrhotic patients poor-responders to nadolol show a pronounced arterial splanchnic vasodilatation at a baseline echo-color-Doppler study. This can be considered a non-invasive clue for the a priori identification of this subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343679     DOI: 10.1016/j.jhep.2005.10.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

1.  Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.

Authors:  Annalisa Berzigotti; Valentina Rossi; Carolina Tiani; Lucia Pierpaoli; Paola Zappoli; Anna Riili; Carla Serra; Pietro Andreone; Maria Cristina Morelli; Rita Golfieri; Cristina Rossi; Donatella Magalotti; Marco Zoli
Journal:  J Gastroenterol       Date:  2011-01-07       Impact factor: 7.527

Review 2.  Duplex Doppler ultrasound examination of the portal venous system: an emerging novel technique for the estimation of portal vein pressure.

Authors:  Ashwani K Singal; Masood Ahmad; Roger D Soloway
Journal:  Dig Dis Sci       Date:  2009-07-23       Impact factor: 3.199

3.  β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.

Authors:  Ujjal Poddar; Upender Shava; Surender Kumar Yachha; Jaya Agarwal; Sheo Kumar; Sanjay S Baijal; Anshu Srivastava
Journal:  Hepatol Int       Date:  2014-09-23       Impact factor: 6.047

4.  Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension.

Authors:  Annalisa Berzigotti; Andrea De Gottardi; Ranka Vukotic; Sith Siramolpiwat; Juan G Abraldes; Juan Carlos García-Pagan; Jaime Bosch
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.